Kyntra Bio (NASDAQ:KYNB) Stock Rating Raised to “Hold” at Zacks Research

Kyntra Bio (NASDAQ:KYNB) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

A number of other equities research analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $43.00 price objective on shares of Kyntra Bio in a research report on Tuesday, September 1st. Lake Street Capital started coverage on shares of Kyntra Bio in a research report on Thursday, September 17th. They set a “buy” rating and a $41.00 price objective for the company. Weiss Ratings downgraded shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday. Finally, Maxim Group initiated coverage on shares of Kyntra Bio in a research note on Tuesday, October 13th. They set a “buy” rating and a $35.00 target price for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kyntra Bio has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Kyntra Bio Stock Up 3.1%

Shares of Kyntra Bio stock opened at $3.68 on Tuesday. Kyntra Bio has a 52-week low of $3.50 and a 52-week high of $10.47. The company has a 50 day moving average of $6.04 and a 200 day moving average of $6.92. The company has a market capitalization of $14.90 million, a P/E ratio of 0.08 and a beta of 1.08.

Institutional Trading of Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC acquired a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is owned by institutional investors and hedge funds.

Kyntra Bio Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.